9. Yoshimura R, Matsuyama M, Hase T, Tsuchida K, Kuratsukuri K, et al. (2003) The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells. Int J Mol Med 12: 861–865. 10. Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, et al. (2010) Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 113: 349–357. 11. Lavrik IN, Golks A, Krammer PH (2005) Caspases: pharmacological manipulation of cell death. J Clin Invest 115: 2665–2672. 12. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157–163. 13. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47–59. 14. Wolf BB, Schuler M, Echeverri F, Green DR (1999) Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/ inhibitor of caspase-activated DNase inactivation. J Biol Chem 274: 30651–30656. 15. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000–5005. 16. Yu JW, Shi Y (2008) FLIP and the death effector domain family. Oncogene 27: 6216–6227. 17. Kim Y, Suh N, Sporn M, Reed JC (2002) An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 277: 22320–22329. 18. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamaki T, et al. (2005) Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 280: 27345–27355. 19. Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y (1999) Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int J Oncol 15: 793–802. 20. Steele LP, Georgopoulos NT, Southgate J, Selby PJ, Trejdosiewicz LK (2006) Differential susceptibility to TRAIL of normal versus malignant human urothelial cells. Cell Death Differ 13: 1564–1576. 21. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, et al. (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 97: 1754–1759. 22. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734–741. 23. Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, et al. (2006) N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res 12: 2780–2787. 24. Boiteux G, Lascombe I, Roche E, Plissonnier ML, Clairotte A, et al. (2009) A- FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer 124: 1820–1828. 25. Oka N, Tanimoto S, Taue R, Nakatsuji H, Kishimoto T, et al. (2006) Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci 97: 1093–1098. 26. Jesenberger V, Jentsch S (2002) Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3: 112–121. 27. Wei S, Yang J, Lee SL, Kulp SK, Chen CS (2009) PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett 276: 119–124. 28. Perez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, et al. (2004) Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 279: 8976–8985. 29. Turturro F, Friday E, Fowler R, Surie D, Welbourne T (2004) Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines. Clin Cancer Res 10: 7022–7030. 30. Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S (2005) 1,1-Bis(39-indolyl)-1- (p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor Ciglitazone Induces Bladder Tumor Cells Apoptosis gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol Pharmacol 68: 1782–1792. 31. Smits VA, Klompmaker R, Vallenius T, Rijksen G, Makela TP, et al. (2000) p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem 275: 30638–30643. 32. Doonan F, Wallace DM, O’Driscoll C, Cotter TG (2009) Rosiglitazone acts as a neuroprotectant in retinal cells via up-regulation of sestrin-1 and SOD-2. J Neurochem 109: 631–643. 33. Michalovitz D, Halevy O, Oren M (1990) Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671–680. 34. Stewart N, Hicks GG, Paraskevas F, Mowat M (1995) Evidence for a second cell cycle block at G2/M by p53. Oncogene 10: 109–115. 35. Vikhanskaya F, Erba E, D’Incalci M, Broggini M (1994) Introduction of wild- type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 22: 1012–1017. 36. Kim YH, Jung EM, Lee TJ, Kim SH, Choi YH, et al. (2008) Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med 44: 1055–1068. 37. Chen F, Kim E, Wang CC, Harrison LE (2005) Ciglitazone-induced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway. Cell Signal 17: 1572–1577. 38. Inoue T, Kamiyama J, Sakai T (1999) Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 274: 32309–32317. 39. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD (1999) Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1: 330–339. 40. Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, et al. (2004) PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol 150: 863–875. 41. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, et al. (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64: 3386–3390. 42. Kamat AM, Lamm DL (2001) Immunotherapy for bladder cancer. Curr Urol Rep 2: 62–69. 43. Schultze K, Bock B, Eckert A, Oevermann L, Ramacher D, et al. (2006) Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down- regulation of FLIP and Survivin. Apoptosis 11: 1503–1512. 44. Senthivinayagam S, Mishra P, Paramasivam SK, Yallapragada S, Chatterjee M, et al. (2009) Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells. J Biol Chem 284: 13577–13588. 45. Lu M, Kwan T, Yu C, Chen F, Freedman B, et al. (2005) Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 280: 6742–6751. 46. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2007) Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 25: 468–475. 47. Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, et al. (2004) siRNA- mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25: 1065–1071. 48. Ku JH, Seo SY, Kwak C, Kim HH (2010) Cytotoxicity and apoptosis by survivin small interfering RNA in bladder cancer cells. BJU Int 106: 1812–1816. 49. O’Connor DS, Grossman D, Plescia J, Li F, Zhang H, et al. (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 97: 13103–13107. 50. Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH, et al. (2005) Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 280: 9519–9527. PLoS ONE | www.plosone.org 12 December 2011 | Volume 6 | Issue 12 | e28354